78 related articles for article (PubMed ID: 36373891)
1. Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies.
Chang CM; Lam HYP
Anticancer Res; 2023 Dec; 43(12):5283-5298. PubMed ID: 38030174
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer.
Schlam I; Giordano A; Tolaney SM
Expert Opin Drug Saf; 2023; 22(12):1149-1156. PubMed ID: 37994878
[TBL] [Abstract][Full Text] [Related]
3. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.
Takeda T; Sugimoto S; Matsumoto J; Iwata N; Nakamoto A; Ozaki AF; Hamano H; Ariyoshi N; Zamami Y
Int J Clin Pharm; 2024 Apr; 46(2):536-541. PubMed ID: 38240964
[TBL] [Abstract][Full Text] [Related]
4. Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract][Full Text] [Related]
5. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.
Buller W; Pallan L; Chu T; Khoja L
J Oncol Pharm Pract; 2023 Dec; 29(8):1825-1835. PubMed ID: 36945886
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer.
Go M; Kimura M; Yamada S; Usami E; Noguchi Y; Yoshimura T
J Pharm Pract; 2024 Apr; ():8971900241247653. PubMed ID: 38652858
[No Abstract] [Full Text] [Related]
8. Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer.
Senín LD; Pancorbo DM; Garcés MYR; Santos-Rubio MD; Calero JB
Curr Oncol; 2024 Jan; 31(1):250-259. PubMed ID: 38248101
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
[TBL] [Abstract][Full Text] [Related]
10. Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
Go M; Noguchi Y; Masuda R; Asano H; Kimura M; Usami E; Yoshimura T
Int J Cancer; 2024 Apr; ():. PubMed ID: 38619193
[TBL] [Abstract][Full Text] [Related]
11. Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells.
Gallanis GT; Sharif GM; Schmidt MO; Friedland BN; Battina R; Rahhal R; Davis JE; Khan IS; Wellstein A; Riegel AT
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980794
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effects of CDK4/6 Inhibitors in Gastric and Colonic Metastases From Breast Cancer: A Case Report.
Sasaki A; Masuda S; Yoshioka T; Saito A; Motomura Y
Cureus; 2024 Jan; 16(1):e52765. PubMed ID: 38389643
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
17. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Funasaka C; Naito Y; Kusuhara S; Nakao T; Nakajima H; Kawamoto M; Baba K; Mamishin K; Kondoh C; Harano K; Matsubara N; Hosono A; Sasaki T; Kawasaki T; Mukohara T
Jpn J Clin Oncol; 2023 Jan; 53(2):105-114. PubMed ID: 36373891
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]